<DOC>
	<DOCNO>NCT00413153</DOCNO>
	<brief_summary>To study effect switch Kaletra Boosted Reyataz glucose , lipid fat HIV-infected patient .</brief_summary>
	<brief_title>Metabolic Effects Switching Kaletra Boosted Reyataz</brief_title>
	<detailed_description>The primary objective study determine tissue specific glucose trafficking patient switch regimen contain Lopinavir/ritonavir ( LPV/r ) one contain atazanavir/ritonavir ( ATV/r ) . Secondary outcome measure interest include insulin sensitivity determine clamp testing , lipid metabolism hepatic glucose production assess use stable isotope technique . We hypothesize switch protease inhibitor ( PI ) ATV/r LPV/r result direct increase glucose uptake muscle visceral adipose tissue association improvement overall whole body insulin sensitivity compare remain LPV/r . We complete prospective randomize trial Human Immunodeficiency Virus ( HIV ) infect patient stable antiretroviral ( ARV ) regimen contain LPV/r least 6 month randomize either switch regimen contain ATV/r remain LPV/r 6 month . Each subject complete Positron Emission Tomography ( PET ) 18-fluorodeoxyglucose ( FDG ) image hyperinsulinemic clamp study baseline 6 month randomization .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>1 . Previously diagnose HIV infection 2 . Age 1865 year 3 . Stable antiviral regimen contain least 2 nucleoside reverse transcriptase inhibitor ( NRTI 's ) LPV/r Â³ 6 mo 4 . CD4 count &gt; 400 cell/mm3 5 . Metabolic complication indicate one hyperinsulinemia ( fast insulin &gt; = 15 mIU/ml ) , hypercholesteremia ( fast total cholesterol &gt; = 200 mg/dL ) , hypertriglyceridemia ( fast triglyceride &gt; = 150 mg/dL ) , treatment lipid lower medication . 1 . Hemoglobin &lt; 11.0 g/dL 2 . History Diabetes Mellitus 3 . Currently medication Diabetes 4 . Therapy glucocorticoid , growth hormone anabolic agent currently within past 3 month 5 . Current substance abuse , include alcohol , cocaine and/or heroin 6 . Any contraindication ATV/r know allergy ATV 7 . Concurrent therapy : Bepridil ; cisapride ; ergot derivative ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) ; indinavir ; irinotecan ; lovastatin ; midazolam ; pimozide ; proton pump inhibitor ( esomeprazole , lansoprazole , omeprazole ) ; rifampin ; simvastatin ; St John 's wort ; triazolam 8 . New serious opportunistic infection past 3 month 9 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Kaletra</keyword>
	<keyword>Reyataz</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Lipids</keyword>
	<keyword>Body Composition</keyword>
	<keyword>Receiving Kaletra</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>